BR0211091A - Métodos para redução de imunogenicidade de polipeptìdeos - Google Patents
Métodos para redução de imunogenicidade de polipeptìdeosInfo
- Publication number
- BR0211091A BR0211091A BR0211091-1A BR0211091A BR0211091A BR 0211091 A BR0211091 A BR 0211091A BR 0211091 A BR0211091 A BR 0211091A BR 0211091 A BR0211091 A BR 0211091A
- Authority
- BR
- Brazil
- Prior art keywords
- polypeptides
- methods
- humans
- therapeutic
- present
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 230000005847 immunogenicity Effects 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 238000012986 modification Methods 0.000 abstract 2
- 230000004048 modification Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6472—Cysteine endopeptidases (3.4.22)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"MéTODOS PARA REDUçãO DE IMUNOGENICIDADE DE POLIPEPTìDEOS". A presente invenção se refere aos campos de imunologia e produtos terapêuticos de proteína. As proteínas terapêuticas são polipeptídeos a serem administrados especialmente a seres humanos. Os polipeptídeos são modificados, pelo que as modificações resultam em uma propensão reduzida do polipeptídeo de estimular uma resposta imune quando da administração ao ser humano. A invenção, portanto, proporciona métodos para o desenvolvimento de polipeptídeos terapêuticos que são menos imunogênicos do que qualquer contraparte não-modificada quando usados in vivo. As modificações usadas de acordo com a presente invenção se referem, por exemplo, à introdução de locais de clivagem de protease, fixação de moléculas diferentes ou inserção de aminoácidos não-naturais.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01117105 | 2001-07-13 | ||
| EP01117267 | 2001-07-17 | ||
| EP01117271 | 2001-07-17 | ||
| PCT/EP2002/007785 WO2003006047A2 (en) | 2001-07-13 | 2002-07-12 | Methods for reducing immunogenicity of polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0211091A true BR0211091A (pt) | 2004-06-15 |
Family
ID=27224206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0211091-1A BR0211091A (pt) | 2001-07-13 | 2002-07-12 | Métodos para redução de imunogenicidade de polipeptìdeos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7939295B2 (pt) |
| EP (1) | EP1409003A2 (pt) |
| JP (1) | JP2004533845A (pt) |
| KR (1) | KR20040018459A (pt) |
| CN (1) | CN1523996A (pt) |
| BR (1) | BR0211091A (pt) |
| CA (1) | CA2453406A1 (pt) |
| HU (1) | HUP0400340A2 (pt) |
| MX (1) | MXPA04000339A (pt) |
| PL (1) | PL367329A1 (pt) |
| WO (1) | WO2003006047A2 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005066152A1 (en) * | 2003-12-30 | 2005-07-21 | The Brigham And Women's Hospital, Inc. | Thiophene derivatives for up-regulating hla-dm activity |
| US20090010966A1 (en) * | 2007-06-21 | 2009-01-08 | Angelica Therapeutics, Inc. | Modified diphtheria toxins |
| WO2009110944A1 (en) * | 2008-02-29 | 2009-09-11 | Angelica Therapeutics, Inc. | Modified toxins |
| AU2011248540B2 (en) * | 2010-04-28 | 2014-11-20 | Oncolmmune, Inc. | Methods of use of soluble CD24 for therapy of rheumatoid arthritis |
| JP2016519651A (ja) | 2013-03-15 | 2016-07-07 | アンジェリカ セラピューティックス，インク． | 改質された毒素 |
| WO2015084986A1 (en) * | 2013-12-03 | 2015-06-11 | The Johns Hopkins University | Methods of evaluating immunodominant epitopes |
| MA41842A (fr) * | 2015-03-31 | 2018-02-06 | Oblique Therapeutics Ab | Nouveaux procédés de sélection d'épitope |
| GB201617002D0 (en) | 2016-10-06 | 2016-11-23 | Oblique Therapeutics Ab | Multi-protease method |
| WO2018170015A1 (en) * | 2017-03-14 | 2018-09-20 | The Regents Of The University Of California | Engineering crispr cas9 immune stealth |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936249B1 (en) * | 1998-04-15 | 2005-08-30 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
-
2002
- 2002-07-12 CN CNA02813544XA patent/CN1523996A/zh active Pending
- 2002-07-12 HU HU0400340A patent/HUP0400340A2/hu unknown
- 2002-07-12 MX MXPA04000339A patent/MXPA04000339A/es not_active Application Discontinuation
- 2002-07-12 WO PCT/EP2002/007785 patent/WO2003006047A2/en not_active Ceased
- 2002-07-12 BR BR0211091-1A patent/BR0211091A/pt not_active Application Discontinuation
- 2002-07-12 KR KR10-2004-7000531A patent/KR20040018459A/ko not_active Withdrawn
- 2002-07-12 PL PL02367329A patent/PL367329A1/xx unknown
- 2002-07-12 JP JP2003511853A patent/JP2004533845A/ja active Pending
- 2002-07-12 US US10/483,153 patent/US7939295B2/en not_active Expired - Fee Related
- 2002-07-12 EP EP02751137A patent/EP1409003A2/en not_active Withdrawn
- 2002-07-12 CA CA002453406A patent/CA2453406A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003006047A3 (en) | 2003-09-25 |
| MXPA04000339A (es) | 2004-05-04 |
| US7939295B2 (en) | 2011-05-10 |
| EP1409003A2 (en) | 2004-04-21 |
| CA2453406A1 (en) | 2003-01-23 |
| US20040185038A1 (en) | 2004-09-23 |
| PL367329A1 (en) | 2005-02-21 |
| CN1523996A (zh) | 2004-08-25 |
| WO2003006047A2 (en) | 2003-01-23 |
| KR20040018459A (ko) | 2004-03-03 |
| JP2004533845A (ja) | 2004-11-11 |
| HUP0400340A2 (hu) | 2004-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0208041A (pt) | Interferon beta modificado com imunogenicidade reduzida | |
| BR0207016A (pt) | Fator neurotrófico derivado de cérebro humano modificado (bdnf) com imunogenicidade reduzida | |
| Kovacs-Nolan et al. | Immunochemical and structural analysis of pepsin-digested egg white ovomucoid | |
| Ferreira et al. | Preparation of ingredients containing an ACE-inhibitory peptide by tryptic hydrolysis of whey protein concentrates | |
| BR0007840A (pt) | Proteìnas de fusão her-2/neu | |
| DE69840962D1 (de) | Adjuvant qs-21 enthaltende zusammensetzungen mit polysorbate oder cyclodextrin als hilfsmittel | |
| BR0207283A (pt) | Anticorpos anti-egfr modificados com imunogenicidade reduzida | |
| DE69934967D1 (de) | Verfahren zur verminderung der immunogenität von proteinen | |
| BR0207325A (pt) | Métodos terapêuticos para doenças associadas com expressão diminuìda de gene de aop-1 ou aop-1 | |
| DE69010206D1 (de) | Stabilisierte protein- oder peptidkonjugate. | |
| DK1151102T3 (da) | Glycosylerede leptinpræparater og relaterede fremgangsmåder | |
| BR0211091A (pt) | Métodos para redução de imunogenicidade de polipeptìdeos | |
| BR0207704A (pt) | Alfa interferon modificado com imunogenicidade reduzida | |
| BR0207015A (pt) | Eritropoientina modificada (epo) com imunogenicidade reduzida | |
| Villas-Boas et al. | Epitopes resistance to the simulated gastrointestinal digestion of β-lactoglobulin submitted to two-step enzymatic modification | |
| BR9509172A (pt) | Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica | |
| BR0207018A (pt) | Leptina modificada com imunogenicidade reduzida | |
| BR0207014A (pt) | Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida. | |
| BRPI0607097A2 (pt) | peptìdeos de papiloma vìrus l2 n-terminais para a indução de anticorpos de neutralização amplamente cruzada | |
| BR0207705A (pt) | Fator neurotrófico ciliar modificado (cntf) com imonogenicidade reduzida | |
| BR0207945A (pt) | Fator estimulante de colÈnia de macrófagos granulócitos modificados (gm-csf) com reduzida imunogenicidade | |
| WO2002074812A3 (en) | Antibodies for preventing and treating attaching and effacing escherichia coli (aeec) associated diseases | |
| BR0207017A (pt) | Fator de crescimento ceratinócito modificado (kgf) com imunogenicidade reduzida | |
| BR0207542A (pt) | Trombopoietina modificada com imunogenicidade reduzida | |
| Seijffers et al. | Partial characterization of human pepsin I, pepsin IIA, pepsin IIB, and pepsin III |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |